Kamada-AAT for Inhalation, Placebo for “Kamada-AAT for Inhalation”
KamadaAATInhaled008
Phase 3 small_molecule active
Quick answer
Kamada-AAT for Inhalation, Placebo for “Kamada-AAT for Inhalation” for Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limitation (40% ≤ FEV1 ≤ 80% of predicted; FEV1/SVC ≤ 70%), and with no history of two or more moderate or one or more severe exacerbations of COPD during the past year. is a Phase 3 program (small_molecule) at Kamada BioPharma Limited at Fieldfisher LLP with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Kamada BioPharma Limited at Fieldfisher LLP
- Indication
- Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limitation (40% ≤ FEV1 ≤ 80% of predicted; FEV1/SVC ≤ 70%), and with no history of two or more moderate or one or more severe exacerbations of COPD during the past year.
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active